Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioptik TechnologyROCO:4161 70 3-1 Month Momentum % is -1.51% as of Sep. 22, 2026. GuruFocus rates ROCO:4161 with a GF Score™ of 70/100 and a GF Value™ of NT$29.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 849 Medical Devices & Instruments companies, Bioptik Technology ranks worse than 53.95% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Bioptik Technology's 3-1 Month Momentum % is -1.51%.
The industry rank for Bioptik Technology's 3-1 Month Momentum % or its related term are showing as below:
ROCO:4161's 3-1 Month Momentum % is ranked worse than 53.95% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.51
vs ROCO:4161: -1.51
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bioptik Technology 3-1 Month Momentum % Related Terms
ROCO:4161 vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Bioptik Technology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a 3-1 Month Momentum % of -1.51% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bioptik Technology and its competitors. According to the industry distribution chart, Bioptik Technology ranks #458 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 53.9%.
Is Bioptik Technology's 3-1 Month Momentum % too high?
Bioptik Technology's current 3-1 Month Momentum % is -1.51%. Based on the distribution chart, Bioptik Technology ranks #458 out of 849 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #458 out of 849 companies for 3-1 Month Momentum %. This places Bioptik Technology in the lower half of its industry. The industry median 3-1 Month Momentum % is 0.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.51, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current 3-1 Month Momentum % is -1.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.80, compared to a current price of NT$22.15 — trading 25.7% below its estimated fair value. The current 3-1 Month Momentum % is -1.51%. Bioptik Technology's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current 3-1 Month Momentum % is -1.51% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$22.15 is trading 25.7% below its estimated GF Value™ of NT$29.80.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
3-1 Month Momentum %: -1.51%
GF Value™: NT$29.80 vs. price of NT$22.15 (25.7% below fair value)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
70GF Score
Get the complete analysis for ROCO:4161
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
